The unique availability of a defined leukemia-enriched self-lipid antigen also provides us with the opportunity to boost the engineered T cell response with mLPA-containing vaccines, in turn stimulating and enhancing the efficacy of the CD1c-targeting ACT strategy. The gene discussed is CD1C; the disease is leukemia.